Galasko DR - Search Results

1

Validation of MicroRNA Biomarkers for Alzheimer's Disease in Human Cerebrospinal Fluid.

Wiedrick JT, Phillips JI, Lusardi TA, McFarland TJ, Lind B, Sandau US, Harrington CA, Lapidus JA, Galasko DR, Quinn JF, Saugstad JA. Wiedrick JT, et al. Among authors: galasko dr. J Alzheimers Dis. 2019;67(3):875-891. doi: 10.3233/JAD-180539. J Alzheimers Dis. 2019. PMID: 30689565 Free PMC article.

2

Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease.

Motter R, Vigo-Pelfrey C, Kholodenko D, Barbour R, Johnson-Wood K, Galasko D, Chang L, Miller B, Clark C, Green R, et al. Motter R, et al. Ann Neurol. 1995 Oct;38(4):643-8. doi: 10.1002/ana.410380413. Ann Neurol. 1995. PMID: 7574461

3

Extrapyramidal motor signs in clinically diagnosed Alzheimer disease.

Ellis RJ, Caligiuri M, Galasko D, Thal LJ. Ellis RJ, et al. Alzheimer Dis Assoc Disord. 1996 Summer;10(2):103-14. doi: 10.1097/00002093-199601020-00008. Alzheimer Dis Assoc Disord. 1996. PMID: 8727172 Review.

4

Assessment of CSF levels of tau protein in mildly demented patients with Alzheimer's disease.

Galasko D, Clark C, Chang L, Miller B, Green RC, Motter R, Seubert P. Galasko D, et al. Neurology. 1997 Mar;48(3):632-5. doi: 10.1212/wnl.48.3.632. Neurology. 1997. PMID: 9065538 Clinical Trial.

5

The impact of apolipoprotein E4 on cause of death in Alzheimer's disease.

Olichney JM, Sabbagh MN, Hofstetter CR, Galasko D, Grundman M, Katzman R, Thal LJ. Olichney JM, et al. Neurology. 1997 Jul;49(1):76-81. doi: 10.1212/wnl.49.1.76. Neurology. 1997. PMID: 9222173

6

An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study.

Galasko D, Bennett D, Sano M, Ernesto C, Thomas R, Grundman M, Ferris S. Galasko D, et al. Alzheimer Dis Assoc Disord. 1997;11 Suppl 2:S33-9. Alzheimer Dis Assoc Disord. 1997. PMID: 9236950 Clinical Trial.

7

CSF tau and Abeta42: logical biomarkers for Alzheimer's disease?

Galasko D. Galasko D. Neurobiol Aging. 1998 Mar-Apr;19(2):117-9. doi: 10.1016/s0197-4580(98)00021-9. Neurobiol Aging. 1998. PMID: 9558144 No abstract available.

8

High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype.

Galasko D, Chang L, Motter R, Clark CM, Kaye J, Knopman D, Thomas R, Kholodenko D, Schenk D, Lieberburg I, Miller B, Green R, Basherad R, Kertiles L, Boss MA, Seubert P. Galasko D, et al. Arch Neurol. 1998 Jul;55(7):937-45. doi: 10.1001/archneur.55.7.937. Arch Neurol. 1998. PMID: 9678311 Clinical Trial.

9

Cerebrospinal fluid levels of A beta 42 and tau: potential markers of Alzheimer's disease.

Galasko D. Galasko D. J Neural Transm Suppl. 1998;53:209-21. J Neural Transm Suppl. 1998. PMID: 9700659 Review.

10

Biological markers and the treatment of Alzheimer's disease.

Galasko D. Galasko D. J Mol Neurosci. 2001 Oct;17(2):119-25. doi: 10.1385/JMN:17:2:119. J Mol Neurosci. 2001. PMID: 11816785 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

475 results

Search Page

Filters